Related Experiment Videos
Metronomic therapy for breast cancer
Hanspreet Kaur1, G Thomas Budd
1Department of Hematology/Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Current Oncology Reports
|December 11, 2003
Summary
Metronomic chemotherapy, a frequent low-dose approach, enhances antiangiogenic effects. Combining it with targeted antiangiogenic drugs shows promise in improving cancer treatment efficacy and reducing resistance.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Conventional chemotherapy primarily targets rapidly dividing tumor cells.
- Cytotoxic agents can also inhibit tumor growth via antiangiogenic mechanisms.
- Metronomic chemotherapy involves frequent, low-dose administration of chemotherapeutics.
Purpose of the Study:
- To explore the antiangiogenic potential of metronomic chemotherapy.
- To investigate the synergistic effects of combining metronomic chemotherapy with antiangiogenic drugs.
- To assess the impact on efficacy, toxicity, and drug resistance in cancer treatment.
Main Methods:
- Review of preclinical studies on metronomic chemotherapy combined with antiangiogenic agents.
- Analysis of preliminary clinical data evaluating this combined approach.
- Emphasis on endothelial-specific drug administration.
Main Results:
- Preclinical data indicate improved efficacy and reduced toxicity/resistance when chemotherapy is integrated with antiangiogenic drugs.
- Preliminary clinical studies suggest similar positive outcomes.
- Metronomic administration optimizes the antiangiogenic properties of chemotherapeutic agents.
Conclusions:
- Concurrent administration of metronomic chemotherapy and antiangiogenic drugs is a promising strategy.
- This approach may overcome limitations of standard high-dose chemotherapy.
- Randomized, controlled clinical trials are needed for further validation.